Category: Regulatory DisclosuresBy adminMarch 1, 2021 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Rameda Reports its FY20 ResultsNextNext post:Disclosure to EGX on GlaxoSmithKline S.A.E response to Rameda’s acquisition requestRelated PostsRameda Announces New Chairman and Additions to its Board of DirectorsJune 3, 2026Rameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025BOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024
